Log in

NASDAQ:IOVA - Iovance Biotherapeutics Stock Price, Forecast & News

$32.16
+0.20 (+0.63 %)
(As of 03/27/2020 04:00 PM ET)
Today's Range
$30.43
Now: $32.16
$33.99
50-Day Range
$19.54
MA: $27.65
$38.85
52-Week Range
$9.28
Now: $32.16
$38.92
Volume1.88 million shs
Average Volume2.61 million shs
Market Capitalization$4.07 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.31
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company's lead product candidate is lifileucel, an adoptive cell therapy that is in Phase II clinical trial using tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors for the treatment of metastatic melanoma. It is also developing LN-145, an autologous adoptive cell therapy to treat cervical and head and neck cancers. The company has research collaboration and clinical grant agreements with Moffitt to evaluate TIL therapy in a clinical trial that combines TIL with nivolumab in NSCLC; strategic alliance agreement with M.D. Anderson Cancer Center to conduct clinical and preclinical research studies; strategic alliance agreement with Roswell Park Cancer Institute to conduct a clinical research study of TIL therapy in bladder cancer; collaboration agreement with MedImmune to conduct clinical and preclinical research in immuno-oncology; preclinical research collaboration with the Ohio State University; and a preclinical research collaboration with Cellectis S.A. to investigate transcription activator-like effector nucleases. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was founded in 2007 and is headquartered in San Carlos, California.
Read More
Iovance Biotherapeutics logo

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:IOVA
CUSIPN/A
Phone650-260-7120

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$2.37 per share

Profitability

Net Income$-197,560,000.00

Miscellaneous

Employees88
Market Cap$4.07 billion
Next Earnings Date5/5/2020 (Estimated)
OptionableOptionable

Receive IOVA News and Ratings via Email

Sign-up to receive the latest news and ratings for IOVA and its competitors with MarketBeat's FREE daily newsletter.


Iovance Biotherapeutics (NASDAQ:IOVA) Frequently Asked Questions

How has Iovance Biotherapeutics' stock been impacted by COVID-19 (Coronavirus)?

Iovance Biotherapeutics' stock was trading at $29.58 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, IOVA stock has increased by 8.7% and is now trading at $32.16. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Iovance Biotherapeutics?

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Iovance Biotherapeutics in the last year. There are currently 14 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Iovance Biotherapeutics.

When is Iovance Biotherapeutics' next earnings date?

Iovance Biotherapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, May 5th 2020. View our earnings forecast for Iovance Biotherapeutics.

How were Iovance Biotherapeutics' earnings last quarter?

Iovance Biotherapeutics Inc (NASDAQ:IOVA) released its quarterly earnings data on Tuesday, February, 25th. The biotechnology company reported ($0.50) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.42) by $0.08. View Iovance Biotherapeutics' earnings history.

What price target have analysts set for IOVA?

14 Wall Street analysts have issued 1-year price objectives for Iovance Biotherapeutics' shares. Their forecasts range from $27.00 to $45.00. On average, they anticipate Iovance Biotherapeutics' stock price to reach $34.62 in the next twelve months. This suggests a possible upside of 7.6% from the stock's current price. View analysts' price targets for Iovance Biotherapeutics.

What are Wall Street analysts saying about Iovance Biotherapeutics stock?

Here are some recent quotes from research analysts about Iovance Biotherapeutics stock:
  • 1. According to Zacks Investment Research, "Iovance Biotherapeutics, Inc. is a biopharmaceutical company. It focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient's own immune system to eradicate cancer cells. Iovance Biotherapeutics Inc., formerly known as Lion Biotechnologies Inc., is based in SAN CARLOS, United States. " (2/25/2020)
  • 2. HC Wainwright analysts commented, "Our thesis on TILs stands strong. In accordance with our thesis, showing efficacy in solid tumors beyond melanoma continues to represent a game changer for Iovance and, on a broader look, we continue to view this company as a viable takeout candidate for Big Pharma. We would like to reiterate that, apart from academic-based TILs therapies such as NCI and MD Anderson, Iovance is the only biotech that is developing a commercial TIL product to treat a variety of tumors and patients using the predefined cryopreserved 22-day manufacturing strategy." (7/2/2019)
  • 3. Chardan Capital analysts commented, "We therefore expect to see a similar rate in the registration-directed Cohort 4 which is currently enrolling." (5/31/2019)

Has Iovance Biotherapeutics been receiving favorable news coverage?

Media stories about IOVA stock have been trending somewhat positive on Saturday, according to InfoTrie Sentiment. InfoTrie ranks the sentiment of press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Iovance Biotherapeutics earned a media sentiment score of 0.8 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the immediate future. View the latest news aboutIovance Biotherapeutics.

Are investors shorting Iovance Biotherapeutics?

Iovance Biotherapeutics saw a drop in short interest in March. As of March 13th, there was short interest totaling 12,825,400 shares, a drop of 11.9% from the February 27th total of 14,560,000 shares. Based on an average trading volume of 2,203,500 shares, the days-to-cover ratio is presently 5.8 days. Currently, 11.1% of the company's stock are short sold. View Iovance Biotherapeutics' Current Options Chain.

Who are some of Iovance Biotherapeutics' key competitors?

What other stocks do shareholders of Iovance Biotherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Iovance Biotherapeutics investors own include Portola Pharmaceuticals (PTLA), Applied Materials (AMAT), Immunomedics (IMMU), Kadmon (KDMN), BlackRock (BLK), CA (CA), Seattle Genetics (SGEN), Micron Technology (MU), Bristol-Myers Squibb (BMY) and Heron Therapeutics (HRTX).

Who are Iovance Biotherapeutics' key executives?

Iovance Biotherapeutics' management team includes the following people:
  • Dr. Maria Fardis, CEO, Pres & Director (Age 51)
  • Mr. Timothy E. Morris, CFO, Principal Accounting Officer, Corp. Sec. & Treasurer (Age 57)
  • Dr. Frederick G. Vogt Ph.D., Esq., Gen. Counsel (Age 45)
  • Mr. Howard B. Johnson, Sr. VP of Corp. Devel., Alliance Management & Program Management (Age 59)
  • Dr. Elma S. Hawkins Ph.D., MBA, Advisor to the Board (Age 62)

What is Iovance Biotherapeutics' stock symbol?

Iovance Biotherapeutics trades on the NASDAQ under the ticker symbol "IOVA."

Who are Iovance Biotherapeutics' major shareholders?

Iovance Biotherapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Perceptive Advisors LLC (7.46%), Perceptive Advisors LLC (7.46%), Farallon Capital Management LLC (4.95%), Franklin Resources Inc. (4.33%), Franklin Resources Inc. (4.34%) and State Street Corp (3.43%). Company insiders that own Iovance Biotherapeutics stock include Iain D Dukes, Merrill A Mcpeak and Wayne P Rothbaum. View institutional ownership trends for Iovance Biotherapeutics.

Which major investors are selling Iovance Biotherapeutics stock?

IOVA stock was sold by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Perceptive Advisors LLC, Franklin Resources Inc., Franklin Resources Inc., Broadfin Capital LLC, State Street Corp, Rafferty Asset Management LLC, and Nuveen Asset Management LLC. View insider buying and selling activity for Iovance Biotherapeutics.

Which major investors are buying Iovance Biotherapeutics stock?

IOVA stock was bought by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Norges Bank, Fairmount Funds Management LLC, Artisan Partners Limited Partnership, Eagle Asset Management Inc., Rothschild & Co. Asset Management US Inc., Crawford Lake Capital Management LLC, and Farallon Capital Management LLC. Company insiders that have bought Iovance Biotherapeutics stock in the last two years include Iain D Dukes, Merrill A Mcpeak, and Wayne P Rothbaum. View insider buying and selling activity for Iovance Biotherapeutics.

How do I buy shares of Iovance Biotherapeutics?

Shares of IOVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Iovance Biotherapeutics' stock price today?

One share of IOVA stock can currently be purchased for approximately $32.16.

How big of a company is Iovance Biotherapeutics?

Iovance Biotherapeutics has a market capitalization of $4.07 billion. The biotechnology company earns $-197,560,000.00 in net income (profit) each year or ($1.59) on an earnings per share basis. Iovance Biotherapeutics employs 88 workers across the globe. View additional information about Iovance Biotherapeutics.

What is Iovance Biotherapeutics' official website?

The official website for Iovance Biotherapeutics is http://www.iovance.com/.

How can I contact Iovance Biotherapeutics?

Iovance Biotherapeutics' mailing address is 999 SKYWAY ROAD SUITE 150, SAN CARLOS CA, 94070. The biotechnology company can be reached via phone at 650-260-7120 or via email at [email protected]


MarketBeat Community Rating for Iovance Biotherapeutics (NASDAQ IOVA)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  463 (Vote Outperform)
Underperform Votes:  268 (Vote Underperform)
Total Votes:  731
MarketBeat's community ratings are surveys of what our community members think about Iovance Biotherapeutics and other stocks. Vote "Outperform" if you believe IOVA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IOVA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/28/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel